GlassScriptPhysician profile
Nicole Dequattro
NPI 1588636583
$2,899.71
in general payments reported to CMS, 2019-2025
28 companies · $860 in 2025
The $860 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $223 · 2021: $423 · 2022: $414 · 2023: $382 · 2024: $325 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.09 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.25 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $405.16 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $288.79 | 2019-2025 | Injectafer |
| Caldera Medical, INC | $204.85 | 2025 | |
| Pfizer INC. | $189.33 | 2021-2024 | |
| Millicent US INC | $127.63 | 2023-2025 | Femlyv, Intrarosa, Femring |
| Avion Pharmaceuticals | $120.06 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $118.01 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $98.26 | 2021-2022 | |
| Shield Therapeutics INC | $96.04 | 2023-2024 | Accrufer |
| Coopersurgical, INC. | $88.08 | 2022-2023 | Mara Console, Advincula Delineator Uterine Manipulator |
| Exeltis, USA INC. | $85.42 | 2022-2024 | Slynd |
| Hologic Sales and Service, LLC | $67.20 | 2022-2025 | Novasure, Myosure Tissue Removal Device |
| Sage Therapeutics, LLC | $61.51 | 2022-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $58.55 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $48.07 | 2021-2023 | Phexxi |
| Aspira Women'S Health INC | $44.87 | 2019-2023 | Ova1 |
| Ethicon US, LLC | $41.54 | 2025 | Stratafix, Ethicon |
| Gilead Sciences, INC. | $34.64 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.17 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $32.88 | 2019-2020 | |
| Organon LLC | $31.10 | 2024-2025 | Nexplanon |
| Mission Pharmacal Company | $29.77 | 2019 | |
| Lupin INC. | $26.74 | 2020 | |
| Mayne Pharma Commercial LLC | $16.42 | 2023 | |
| Amgen INC. | $15.26 | 2025 | Evenity |
| Supernus Pharmaceuticals, INC. | $14.85 | 2025 | Qelbree |
| Meditrina | $2.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Dequattro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.